Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
The Associated Press - Business News on MSN14d
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024Copyright 2025 The Associated Press. All Rights Reserved. A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017 ...
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback